Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
12:46pm, Tuesday, 16'th Jul 2024
Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD'
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
11:30am, Tuesday, 16'th Jul 2024
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia Pharmaceuticals: Back In The Buy Zone
11:32am, Sunday, 23'rd Jun 2024
Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett
New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings
09:00am, Tuesday, 18'th Jun 2024
BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combine
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 07'th Jun 2024
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
11:46pm, Wednesday, 05'th Jun 2024
ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkin
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 17'th May 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted ind
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia's Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV produ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:58pm, Thursday, 09'th May 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside C
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
07:01am, Thursday, 09'th May 2024
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
09:00pm, Wednesday, 08'th May 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communica
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
06:16pm, Wednesday, 08'th May 2024
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
11:41am, Monday, 06'th May 2024
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 01'st May 2024
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
